Cancer risk in women exposed to diethylstilbestrol in utero. 1998

E E Hatch, and J R Palmer, and L Titus-Ernstoff, and K L Noller, and R H Kaufman, and R Mittendorf, and S J Robboy, and M Hyer, and C M Cowan, and E Adam, and T Colton, and P Hartge, and R N Hoover
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892-7362, USA.

BACKGROUND The association between in utero exposure to diethylstilbestrol (DES) and clear cell adenocarcinoma (CCA) of the vagina and cervix is well known, yet there has been no systematic study of DES-exposed daughters to determine whether they have an increased risk of other cancers. As many as 3 million women in the United States may have been exposed to DES in utero. OBJECTIVE To determine whether women exposed to DES in utero have a higher risk of cancer after an average of 16 years of follow-up. METHODS A cohort study with mailed questionnaires and medical record review of reported cancer outcomes. METHODS A cohort of 4536 DES-exposed daughters (of whom 81% responded) and 1544 unexposed daughters (of whom 79% responded) who were first identified in the mid-1970s. METHODS Cancer incidence in DES-exposed daughters compared with population-based rates and compared with cancer incidence in unexposed daughters. RESULTS To date, DES-exposed daughters have not experienced an increased risk for all cancers (rate ratio, 0.96; 95% confidence interval [CI], 0.58-1.56) or for individual cancer sites, except for CCA. Three cases of vaginal CCA occurred among the exposed daughters, resulting in a standardized incidence ratio of 40.7 (95% CI, 13.1-126.2) in comparison with population-based incidence rates. The rate ratio for breast cancer was 1.18 (95% CI, 0.56-2.49); adjustment for known risk factors did not alter this result. CONCLUSIONS Thus far, DES-exposed daughters show no increased cancer risk, except for CCA. Nevertheless, because exposed daughters included in our study were, on average, only 38 years old at last follow-up, continued surveillance is warranted to determine whether any increases in cancer risk occur during the menopausal years.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011297 Prenatal Exposure Delayed Effects The consequences of exposing the FETUS in utero to certain factors, such as NUTRITION PHYSIOLOGICAL PHENOMENA; PHYSIOLOGICAL STRESS; DRUGS; RADIATION; and other physical or chemical factors. These consequences are observed later in the offspring after BIRTH. Delayed Effects, Prenatal Exposure,Late Effects, Prenatal Exposure
D002583 Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX. Cancer of Cervix,Cancer of the Cervix,Cancer of the Uterine Cervix,Cervical Cancer,Cervical Neoplasms,Cervix Cancer,Cervix Neoplasms,Neoplasms, Cervical,Neoplasms, Cervix,Uterine Cervical Cancer,Cancer, Cervical,Cancer, Cervix,Cancer, Uterine Cervical,Cervical Cancer, Uterine,Cervical Cancers,Cervical Neoplasm,Cervical Neoplasm, Uterine,Cervix Neoplasm,Neoplasm, Cervix,Neoplasm, Uterine Cervical,Uterine Cervical Cancers,Uterine Cervical Neoplasm
D004054 Diethylstilbestrol A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed) Stilbestrol,Agostilben,Apstil,Diethylstilbestrol, (Z)-Isomer,Diethylstilbestrol, Disodium Salt,Distilbène,Stilbene Estrogen,Tampovagan,Estrogen, Stilbene
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor

Related Publications

E E Hatch, and J R Palmer, and L Titus-Ernstoff, and K L Noller, and R H Kaufman, and R Mittendorf, and S J Robboy, and M Hyer, and C M Cowan, and E Adam, and T Colton, and P Hartge, and R N Hoover
January 2015, Therapie,
E E Hatch, and J R Palmer, and L Titus-Ernstoff, and K L Noller, and R H Kaufman, and R Mittendorf, and S J Robboy, and M Hyer, and C M Cowan, and E Adam, and T Colton, and P Hartge, and R N Hoover
April 2009, Journal of women's health (2002),
E E Hatch, and J R Palmer, and L Titus-Ernstoff, and K L Noller, and R H Kaufman, and R Mittendorf, and S J Robboy, and M Hyer, and C M Cowan, and E Adam, and T Colton, and P Hartge, and R N Hoover
December 1983, The Journal of reproductive medicine,
E E Hatch, and J R Palmer, and L Titus-Ernstoff, and K L Noller, and R H Kaufman, and R Mittendorf, and S J Robboy, and M Hyer, and C M Cowan, and E Adam, and T Colton, and P Hartge, and R N Hoover
September 2017, Therapie,
E E Hatch, and J R Palmer, and L Titus-Ernstoff, and K L Noller, and R H Kaufman, and R Mittendorf, and S J Robboy, and M Hyer, and C M Cowan, and E Adam, and T Colton, and P Hartge, and R N Hoover
September 1988, Advances in contraception : the official journal of the Society for the Advancement of Contraception,
E E Hatch, and J R Palmer, and L Titus-Ernstoff, and K L Noller, and R H Kaufman, and R Mittendorf, and S J Robboy, and M Hyer, and C M Cowan, and E Adam, and T Colton, and P Hartge, and R N Hoover
June 2000, The New England journal of medicine,
E E Hatch, and J R Palmer, and L Titus-Ernstoff, and K L Noller, and R H Kaufman, and R Mittendorf, and S J Robboy, and M Hyer, and C M Cowan, and E Adam, and T Colton, and P Hartge, and R N Hoover
May 1981, American journal of obstetrics and gynecology,
E E Hatch, and J R Palmer, and L Titus-Ernstoff, and K L Noller, and R H Kaufman, and R Mittendorf, and S J Robboy, and M Hyer, and C M Cowan, and E Adam, and T Colton, and P Hartge, and R N Hoover
January 1980, Fertility and sterility,
E E Hatch, and J R Palmer, and L Titus-Ernstoff, and K L Noller, and R H Kaufman, and R Mittendorf, and S J Robboy, and M Hyer, and C M Cowan, and E Adam, and T Colton, and P Hartge, and R N Hoover
July 1980, Obstetrics and gynecology,
E E Hatch, and J R Palmer, and L Titus-Ernstoff, and K L Noller, and R H Kaufman, and R Mittendorf, and S J Robboy, and M Hyer, and C M Cowan, and E Adam, and T Colton, and P Hartge, and R N Hoover
September 2017, Therapie,
Copied contents to your clipboard!